Abstract
Guillain-Barré syndrome (GBS) is a relatively common, potentially lethal disease of a presumed autoimmune origin, known to cause a progressive flaccid paralysis. The treatment of GBS consists of both supportive and immunomodulatory treatments, among which intravenous immunoglobulin (IVIg) and plasma exchange (PE) are considered most effective. A number of randomized, controlled studies have shown IVIg to be at least as effective as PE in the treatment of GBS, and in some cases superior. Moreover, IVIg has been found to be safer than PE, having a lower frequency of multiple complications. IVIg has also been found to be both effective and safe in the treatment of pediatric patients with GBS. Thus, its efficacy, safety, and availability make IVIg the treatment of choice in many patients with GBS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kuwabara, S. (2004), Drugs 64, 597–610.
Dalakas, M. C. (2004), JAMA 291, 2367–2375.
Czaplinski, A. and Steck, A. J. (2004), J Neurol 251, 127–137.
Ibanez, C. and Montoro-Ronsano J. B. (2003), Curr Pharm Biotechnol 4, 239–247.
Zhang, G., Lopez, P. H. H., Li, C. I., et al. (2004), Brain 127, 1085–1100.
Stabgel, M., Toyka, K. V., and Gold, R. (1999), Arch Neurol 56, 661–663.
Nishimoto, Y., Koga, M., Kamijo, M., Hirata, K., and Yuki, N. (2004), Neurology 62, 1939–1944.
van der Meche, F. G. and Schmitz, P. I. (1992), N Engl J Med 326, 1123–1129.
Bril, V., Ilse, W. K., Pearce, R., Dhanani, A., Sutton, D., and Kong, K. (1996), Neurology 46, 100–103.
Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. (1997), Lancet 349, 225–230.
van Koningsveld, R., Schmitz, P. I., Meche, F. G., Visser, L. H., Meulstee, J., van Doorn, P. A.; Dutch GBS Study Group (2004), Lancet 363, 192–196.
Jacobs, B. C., van Doorn, P. A., Schmitz, P. I., et al. (1996), Ann Neurol 40, 181–187.
Kuwabara, S., Mori, M., Ogawara, K., et al. (2001), Muscle Nerve 24, 54–58.
Dada, M. A. and Kaplan, A. A. (2004) Ther Apher Dial 8, 409–412.
Gurses, N., Uysal, S., Cetinkaya, F., Islek, I. and Kalayci, A.G. (1995), Scand J Infect Dis 27, 241–243.
Yata, J., Nihei, K., Ohya, T., et al.; Study Group for Pediatric Guillain-Barré Syndrome. (2003), Pediatr Int 45, 543–549.
Shahar, E. and Leiderman, M. (2003), Clin Neuropharmacol 26, 84–87.
Raphael, J. C., Chevret, S., Harboun, M., and Jars-Guincestre, M. C.; French Guillain-Barré Syndrome Cooperative Group. (2001), J Neurol Neurosurg Psychiatry 71, 235–238.
Katz, U. and Orbach, H. (2005), Clin Rev Allergy Immunol This issue.
Dalakas, M. C. (2004), Pharmacol Ther 102, 177–193.
Hughes, R. A., Wijdicks, E. F., Barohn, R., et al.; Quality Standards Subcommittee of the American Academy of Neurology. (2003), Neurology 61, 736–740.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Harel, M., Shoenfeld, Y. Intravenous immunoglobulin and guillain-barré syndrome. Clinic Rev Allerg Immunol 29, 281–287 (2005). https://doi.org/10.1385/CRIAI:29:3:281
Issue Date:
DOI: https://doi.org/10.1385/CRIAI:29:3:281